Adefovir dipivoxil in chronic hepatitis B: history and current uses

Bibliography

• Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Hepatitis B Information for Health Professionals. Available from: http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview [Last accessed 26 August 2011]
   Google Scholar
• EASL Clinical Practice Guidelines: management of chronic hepatitis B. European Association for the Study of the Liver. J Hepatol 2009;50(2):227-42
   PubMedGoogle Scholar
• Liaw Y-F, Leung N, Kao J-H, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-83
   PubMed Web of Science ®Google Scholar
• Jafri S-MR, Lok AS-F. Antiviral therapy for chronic hepatitis B. Clin Liver Dis 2010;14:425-38
   PubMed Web of Science ®Google Scholar
• Yoo BC, Kim JH, Chung Y-H, Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-8
   PubMed Web of Science ®Google Scholar
• Yoo BC, Kim JH, Kim T-H, Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-8
   PubMed Web of Science ®Google Scholar
• Yoon EL, Yim HJ, Lee HJ, Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two year follow-up data. J Clin Gastroenterol 2011;45:893-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21617542 [ Last accessed 25 August 2011]
   PubMedGoogle Scholar
• Shin SR, Yoo BC, Choi MS, A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naive patients with chronic hepatitis B. Hepatol Int 2011;5:664-70
   PubMedGoogle Scholar
• Gilead Sciences. Highlights of prescribing information for hepsera (adefovir dipivoxil). Available from: www.gilead.com/pdf/hepsera_pi.pdf [Last accessed 26 August 2011]
   Google Scholar
• Kahn J, Lagakos S, Wulfsohn M, Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999;282:2305-12
   PubMed Web of Science ®Google Scholar
• Mellors JW. Adefovir for the treatment of HIV infection: if not now, when? JAMA 1999;282:2355-6
   PubMedGoogle Scholar
• Gilead Sciences. Gilead Sciences announces termination of its U.S. development program for adefovir dipivoxil for HIV. Available from: http://www.gilead.com/pr_944254502 [Last accessed 26 August 2011]
   Google Scholar
• Ray AS, Vela JE, Olson L, Effective metabolism and long intracellular half life of the anti-hepatitis B agent adefovir in hepatic cells. Biochem Pharmacol 2004;68:1825-31
   PubMedGoogle Scholar
• Marcellin P, Chang T-T, Lim SG, Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang T-T, Lim SGL, Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. Engl J Med 2003;348:800-7
   PubMed Web of Science ®Google Scholar
• Westland C, Delaney W IV, Yang H, Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003;125:107-16
   PubMed Web of Science ®Google Scholar
• Perrillo R, Schiff E, Yoshida E, Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34
   PubMed Web of Science ®Google Scholar
• Perrillo R, Hann H-W, Mutimer D, Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90
   PubMed Web of Science ®Google Scholar
• Peters MG, Hann H, Martin P, Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101
   PubMed Web of Science ®Google Scholar
• Rapti I, Dimou E, Mitsoula P, Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-13
   PubMed Web of Science ®Google Scholar
• Vassiliadis TG, Giouleme O, Koumerkeridis G, Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg− chronic hepatitis B patients: a 4-year study. J Gastroenterol Hepatol 2010;25:54-60
   PubMed Web of Science ®Google Scholar
• Lee JM, Park JY, Kim DY, Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther (Lond) 2010;15:235-41
   PubMed Web of Science ®Google Scholar
• Chung GE, Kim W, Lee KL, Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. Dig Dis Sci 2011;56:2130-6
   PubMed Web of Science ®Google Scholar
• Westland CE, Yang H, Delaney WE IV, Week 48 resistance surveillance in two phase III clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003;38:96-103
   PubMed Web of Science ®Google Scholar
• Lee Y-S, Suh DJ, Lim Y-S, Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43:1385-91
   PubMed Web of Science ®Google Scholar
• Yeon JE, Yoo W, Hong SP, Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006;55:1488-95
   PubMed Web of Science ®Google Scholar
• Fung SK, Chae HB, Fontana RJ, Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-90
   PubMed Web of Science ®Google Scholar
• Chen C-H, Wang J-H, Lu S-N, Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience. Liver Int 2011;31:206-14
   PubMedGoogle Scholar
• Tan J, Degertekin B, Wong SN, Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008;48:391-8
   PubMed Web of Science ®Google Scholar
• Berg T, Marcellin P, Zoulim F, Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010;139:1207-17
   PubMed Web of Science ®Google Scholar
• van Bommel F, de Man RA, Wedemeyer H, Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
   PubMed Web of Science ®Google Scholar
• Hui C-K, Zhang H-Y, Bowden S, 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008;48:714-20
   PubMed Web of Science ®Google Scholar
• Wursthorn K, Lutgehetmann M, Dandri M, Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84
   PubMed Web of Science ®Google Scholar
• Lutgehetmann M, Volzt T, Quaas A, Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther (Lond) 2008;13:57-66
   PubMed Web of Science ®Google Scholar
• Moucari R, Boyer N, Ripault M-P, Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. J Viral Hepat 2011;18:580-6
   PubMed Web of Science ®Google Scholar
• Cao Z, Yu H, Ma L, Peginterferon alfa-2a (40kD) plus adefovir for 96 weeks in HBeAg-negative CHB results in high rates of HBsAg clearance/seroconvesion. J Hepatol 2011;54(Suppl 1):S283
   Google Scholar
• Cao Z, Zhang Y, Ma L, Treatment of HBeAg-positive CHB infection with peginterferon alfa-2a [40kD] plus lamivudine or adefovir for 96 weeks results in high rates of HBsAg clearance/seroconversion. Hepatology 2010;52(Suppl S1):507A
   Google Scholar
• Chen X, Cao Z, Liu Y, A Potent HBsAg response to treatment of HBeAg-positive chronic hepatitis B with interferon alpha plus a nucleos(t)ide analogue. J Gastroenterol Hepatol 2011; Epub 2011 Nov 18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22098411 [Last accessed 28 November 2011]
   Google Scholar
• Marcellin P, Heathcote EJ, Buti M, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Marcellin P, Buti M, Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-43
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Raptopoulou-Gigi M, Cheinquer H, Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91-100
   PubMed Web of Science ®Google Scholar
• Ryu HJ, Lee JM, Ahn SH, Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol 2010;82:1835-42
   PubMed Web of Science ®Google Scholar
• Sokal EM, Kelly D, Wirth S, The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. J Clin Pharmacol 2008;48:512-17
   PubMedGoogle Scholar
• Jonas MM, Kelly D, Pollack H, Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to < 18 years) with chronic hepatitis B. Hepatology 2008;47:1863-71
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, Thibault V, Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-23
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Thibault V, Vig P, Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006;44:62-7
   PubMed Web of Science ®Google Scholar
• Hannon H, Bagnis CI, Benhamou Y, The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV. Nephrol Dial Transplant 2004;19:386-90
   PubMedGoogle Scholar
• Peters MG, Andersen J, Lynch P, Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44:1110-16
   PubMed Web of Science ®Google Scholar
• Lacombe K, Gozlan J, Boyd A, Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients. Antivir Ther (Lond) 2008;13:705-13
   PubMedGoogle Scholar
• Ingiliz P, Valantin M-A, Thibault V, Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. Antivir Ther (Lond) 2008;13:895-900
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Last accessed 26 August 2011]
   Google Scholar
• Sheldon JA, Corral A, Rodes B, Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005;19:2036-8
   PubMedGoogle Scholar
• Delaugerre C, Marcelin A-G, Thibault V, Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002;46:1586-8
   PubMed Web of Science ®Google Scholar
• Republique Francaise Ministere de la Sante, et des Sports. Rapport 2010 sous la direction du Pr. Patrick Yeni: Prise en charge medicale des personnes infectees par le VIH. 2010. Available from: http://www.sante.gouv.fr/rapport-2010-sur-la-prise-en-charge-medicale-des-personnes-infectees-par-le-vih-sous-la-direction-du-pr-patrick-yeni.html [Last accessed 1 September 2011]
   Google Scholar
• Seaberg EC, Belle SH, Beringer KC, Liver transplantation in the United States from 1987 – 1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin Transpl 1998;17-37
   PubMedGoogle Scholar
• Akyildiz M, Karasu Z, Zeytunlu M, Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007;22:2130-4
   PubMed Web of Science ®Google Scholar
• Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39
   PubMed Web of Science ®Google Scholar
• Schiff E, Lai C-L, Hadziyannis S, Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007;13:349-60
   PubMed Web of Science ®Google Scholar
• Lo CM, Liu CL, Lau GK, Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005;11:807-13
   PubMed Web of Science ®Google Scholar
• Osborn MK, Han SH, Regev A, Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol 2007;5:1454-61
   PubMedGoogle Scholar
• Marzano A, Lampertico P, Mazzaferro V, Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005;11:532-8
   PubMedGoogle Scholar
• Freshwater DA, Dudley T, Cane P, Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 2008;85:1105-11
   PubMedGoogle Scholar
• Angus PW, Patterson SJ, Strasser SI, A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008;48:1460-6
   PubMed Web of Science ®Google Scholar
• Neff GW, Kemmer N, Kaiser TE, Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007;52:2497-500
   PubMed Web of Science ®Google Scholar
• Nath DS, Kalis A, Nelson S, Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006;20:206-10
   PubMed Web of Science ®Google Scholar
• Katz LH, Tur-Kaspa R, Guy DG, Paul M. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. Cochrane Database Syst Rev 2010;7:CD006005
   Google Scholar
• Gane E, Strasser S, Patterson S, A prospective study on the safety and efficacy of lamivudine and adefovir dipivoxil prophylaxis in HBsAg positive liver transplantation candidates. Hepatology 2007;46(Suppl 1):479A
   Google Scholar
• Yang Y, Zhang Q, Cai C-jie, Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. Chin Med J 2007;120:1400-3
   PubMed Web of Science ®Google Scholar
• Wai C-T, Prabhakaran K, Wee A, Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. Transplant Proc 2004;36:2313-14
   PubMedGoogle Scholar
• Herreros de Tejada Echanojauregui A, Moreno Planas JM, Rubio Gonzalez E, Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus. Transplant Proc 2005;37:1507-8
   PubMedGoogle Scholar
• Limquiaco JL, Wong J, Wong VWS, Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. J Med Virol 2009;81:224-9
   PubMed Web of Science ®Google Scholar
• Chan HL-Y, Chui AK-K, Lau W-Y, Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant 2004;18:295-300
   PubMed Web of Science ®Google Scholar
• Hwang S, Ahn C-S, Song G-W, Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on. Liver Transpl 2011;17:456-65
   PubMedGoogle Scholar
• Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49(5 Suppl):S185-95
   PubMed Web of Science ®Google Scholar
• Spiegel PB. The effects of antiretroviral therapy on HIV prevalence in conflict situations: not yet there. AIDS 2009;23:541-2
   PubMedGoogle Scholar
• Fisher EJ, Chaloner K, Cohn DL, The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001;15:1695-700
   PubMed Web of Science ®Google Scholar
• Fontaine H, Vallet-Pichard A, Chaix M-L, Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005;80:1086-92
   PubMed Web of Science ®Google Scholar
• Kamar N, Huart A, Tack I, Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. Clin Nephrol 2009;71:36-42
   PubMed Web of Science ®Google Scholar
• Ha NB, Ha NB, Garcia RT, Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009;50:727-34
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot JS, Launay-Vacher V, Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004;66:1153-8
   PubMed Web of Science ®Google Scholar
• Cohen SM, Levy RM, Jovanovich JF, Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol 2009;43:1008-10
   PubMed Web of Science ®Google Scholar
• Wong T, Girgis CM, Ngu MC, Hypophosphatemic osteomalacia after low-dose adefovir dipivoxil therapy for hepatitis B. J Clin Endocrinol Metab 2010;95:479-80
   PubMed Web of Science ®Google Scholar
• Tamori A, Enomoto M, Kobayashi S, Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat 2010;17:123-9
   PubMed Web of Science ®Google Scholar
• Stornaiuolo G, Amato A, Gaeta GB. Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B. Dig Liver Dis 2006;38:211-12
   PubMedGoogle Scholar
• Weber A, Carbonnel F, Simon N, Severe acute pancreatitis related to the use of adefovir in a liver transplant recipient. Gastroenterol Clin Biol 2008;32:247-9
   PubMedGoogle Scholar
• Yuen M-F, Lai C-L. Adefovir dipivoxil in chronic hepatitis B infection. Expert Opin Pharmacother 2004;5:2361-7
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study to evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) in combination with peginterferon alfa-2a vs standard of care tenofovir disoproxil fumarate monotherapy or peginterferon alfa-2a monotherapy for 48 weeks in chronic hepatitis B (CHB). Available from: http://clinicaltrials.gov/ct2/show/NCT01277601 [Last accessed 19 September 2011]
   Google Scholar